



KSI Research

Technical Recommendation

Jakarta Composite Index Range Today

6,785 – 6,700

Support

6,970 – 7,000 / 7,250

Resistance

Published on 09 May 2025



Jakarta Composite Index

As previously predicted by **KIWOOM RESEARCH**, JCI posted a red candle yesterday following the Doji formed the previous day. A reversal potential when approaching the psychological Resistance of 7,000 had already been anticipated, although JCI had to correct by 98.5 points / -1.42% to the level of 6,827.75. Today, JCI is expected to land at the MA10 Support / around 6,785 – 6,780. Investors/traders are reminded that approaching the long-weekend holiday, portfolio trimming or a Wait & See stance is most appropriate at this time, although the Buy on Weakness momentum also seems tempting along with the short-term uptrend pattern that has begun to form.

ADVICE: HOLD; WAIT & SEE.



BBTN

Bank Tabungan Negara (Persero) Tbk.



(BBTN). Price successfully breakout resistance with potential to continue uptrend. Strength is supported by a golden cross on the Stochastic, a bullish MACD line and positive histogram, along with significantly increased volume.


ADVICE: Trading buy or consider a buy on weakness strategy during a pullback at the support area.

Entry Buy	Target Price	Support	Cut Loss
1,120 – 1,160	1,210 – 1,260	1,100 – 1,120	1,090



HEAL

Medikaloka Hermina Tbk.



(HEAL). Price closed bullish and remains within the consolidation area, with a potential formation of a bullish pennant pattern. Strength is supported by a bullish MACD line and positive histogram, with slightly increased volume.


ADVICE: Trading buy or buy on breakout of the pattern.

Entry Buy	Target Price	Support	Cut Loss
1,210 – 1,255	1,310 – 1,365	1,195 – 1,210	1,185



ICBP

Indofood CBP Sukses Makmur Tbk.



(ICBP). Price successfully rebounded and was able to stay above 11,075 (as a support area). Strength is supported by a golden cross on the Stochastic, a bullish MACD line, and positive histogram.

ADVICE: Trading buy or accumulation buy.

Entry Buy	Target Price	Support	Cut Loss
11,075 – 11,400	11,850 – 12,300	10,900 – 11,075	10,850



KLBF

Kalbe Farma Tbk.



(KLBF). Price continued to rally and remains on an uptrend track. Strength is supported by a bullish Stochastic movement, bullish MACD line, positive histogram, and an increasing volume trend.

ADVICE: Trading buy or averaging up.

Entry Buy	Target Price	Support	Cut Loss
1,390 – 1,440	1,500 – 1,560	1,360 – 1,390	1,350




Forecast – Technical Analysis

Ticker	MA5	RSI Rec	MACD Trend	Recomm,	Pivot Point	Support 1	Support 2	Resistance 1	Resistance 2	Stop Loss Level
JCI	Negative	Overbought	Positive	Sell	6,900	6,825	6,750	6,950	7,025	6,650
ACES	Positive	Trading	Positive	Spec. Buy	535	525	505	555	565	499
ADMR	Negative	Trading	Negative	Sell	910	895	885	920	935	870
ADRO	Positive	Trading	Positive	Spec. Buy	1,895	1,875	1,845	1,925	1,945	1,820
AKRA	Positive	Trading	Positive	Spec. Buy	1,250	1,230	1,220	1,260	1,280	1,200
AMMN	Negative	Overbought	Positive	Sell	7,375	7,225	7,000	7,600	7,750	6,900
AMRT	Negative	Overbought	Positive	Sell	2,345	2,310	2,275	2,380	2,415	2,240
ANTM	Negative	Overbought	Positive	Sell	2,715	2,565	2,455	2,825	2,975	2,415
ARTO	Negative	Trading	Positive	Hold	1,920	1,820	1,760	1,980	2,080	1,735
ASII	Positive	Trading	Negative	Hold	4,840	4,745	4,690	4,895	4,990	4,615
BBCA	Negative	Trading	Positive	Hold	9,050	8,900	8,775	9,175	9,325	8,625
BBNI	Positive	Trading	Positive	Spec. Buy	4,145	4,070	4,005	4,210	4,285	3,945
BBRI	Negative	Trading	Positive	Hold	3,860	3,760	3,680	3,940	4,040	3,625
BBTN	Negative	Overbought	Positive	Sell	1,125	1,060	1,010	1,175	1,240	990
BMRI	Negative	Trading	Positive	Hold	4,890	4,760	4,655	4,995	5,125	4,585
BRIS	Negative	Trading	Positive	Hold	2,810	2,705	2,590	2,925	3,030	2,550
BRPT	Negative	Overbought	Positive	Sell	840	820	790	870	890	780
CPIN	Negative	Overbought	Positive	Sell	4,875	4,805	4,765	4,915	4,985	4,690
CTRA	Negative	Overbought	Positive	Sell	970	950	920	1,000	1,020	905
ESSA	Negative	Trading	Positive	Hold	625	605	590	640	660	580
EXCL	Negative	Trading	Positive	Hold	2,160	2,120	2,090	2,190	2,230	2,060
GOTO	Positive	Trading	Positive	Spec. Buy	84	80	78	86	90	76
ICBP	Positive	Overbought	Positive	Hold	11,275	11,150	10,975	11,450	11,575	10,800
INCO	Negative	Overbought	Positive	Sell	2,825	2,730	2,655	2,900	2,995	2,615
INDF	Positive	Trading	Positive	Spec. Buy	7,750	7,675	7,550	7,875	7,950	7,450
INKP	Negative	Overbought	Positive	Sell	5,650	5,550	5,425	5,775	5,875	5,350
ISAT	Negative	Trading	Positive	Hold	1,905	1,860	1,805	1,960	2,005	1,780
ITMG	Negative	Trading	Negative	Sell	22,275	22,050	21,825	22,500	22,725	21,500
JPFA	Positive	Trading	Negative	Hold	1,785	1,750	1,715	1,820	1,855	1,690
JSMR	Positive	Trading	Negative	Hold	4,160	3,995	3,870	4,285	4,450	3,810
KLBF	Negative	Overbought	Positive	Sell	1,415	1,385	1,335	1,465	1,495	1,315
MAPA	Negative	Trading	Positive	Hold	750	725	705	770	795	695
MAPI	Positive	Trading	Positive	Spec. Buy	1,350	1,335	1,320	1,365	1,380	1,300
MBMA	Negative	Trading	Positive	Hold	353	341	331	363	375	326
MDKA	Negative	Overbought	Positive	Sell	1,865	1,760	1,695	1,930	2,035	1,670
MEDC	Negative	Trading	Negative	Sell	1,055	1,040	1,015	1,080	1,095	1,000
PGAS	Positive	Trading	Negative	Hold	1,620	1,595	1,575	1,640	1,665	1,550
PGEO	Negative	Overbought	Positive	Sell	950	935	915	970	985	900
PTBA	Positive	Trading	Negative	Hold	2,745	2,710	2,675	2,780	2,815	2,635
SIDO	Positive	Trading	Negative	Hold	535	535	525	545	545	520
SMGR	Positive	Trading	Positive	Spec. Buy	2,530	2,430	2,380	2,580	2,680	2,345
SMRA	Negative	Trading	Positive	Hold	436	426	414	448	458	408
TLKM	Positive	Trading	Positive	Spec. Buy	2,605	2,565	2,535	2,635	2,675	2,495
TOWR	Negative	Overbought	Positive	Sell	605	585	580	610	630	570
UNTR	Positive	Oversold	Negative	Spec. Buy	21,625	21,450	21,300	21,775	21,950	20,975
UNVR	Negative	Overbought	Positive	Sell	1,790	1,765	1,730	1,825	1,850	1,700



Kiwoom Research Team



Liza Camelia Suryanata

Head of Equity Research
liza.camelia@kiwoom.co.id



Sukarno Alatas

Senior Equity Research Analyst
sukarno@kiwoom.co.id




Abdul Azis Setyo W.

Equity Research Analyst
azis@kiwoom.co.id



Miftahul Khaer

Equity Research Analyst
khaer.miftahul@kiwoom.co.id



Wahyu Saputra

Equity Research Associate
wahyu.saputra@kiwoom.co.id



HEAD OFFICE

Treasury Tower 27th Floor Unit A, District 8 Kawasan SCBD Lot 28,
Jl.Jend.Sudirman Kav 52-53, Jakarta Selatan 12190

Tel : (021) 5010 5800
Fax : (021) 5010 5820
Email : cs@kiwoom.co.id

PT Kiwoom Sekuritas Indonesia is licensed and supervised by the Financial Services Authority (OJK)

OTHER DISCLOSURES

All Kiwoom's research reports made available to clients are simultaneously available on our own website <http://www.kiwoom.co.id/>. Not all research content is redistributed, e-mailed or made available to third-party aggregators. For all research reports available on a particular stock, please contact your sales representative. Any data discrepancies in this report could be the result of different calculations and/or adjustments.

DISCLAIMER

This report has been prepared and issued by PT Kiwoom Sekuritas Indonesia. Information has been obtained from sources believed to be reliable but Kiwoom Securities do not warrant its completeness or accuracy. Forward-looking information or statements in this report contain information that is based on forecast of future results, estimates of amounts not yet determinable, assumptions, and therefore involve known and unknown risks and uncertainties which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations. To the fullest extent allowed by law, PT Kiwoom Sekuritas Indonesia shall not be liable for any direct, indirect or consequential losses, loss of profits, damages, costs or expenses incurred or suffered by any person or organization arising from reliance on or use of any information contained on this report. The information that we provide should not be construed in any manner whatsoever as, personalized advice. No mention of a particular security in this report constitutes a recommendation to buy, sell or hold that or any security, or that any particular security, portfolio of securities, transaction or investment strategy is suitable for any specific person. This report is being supplied to you solely for your information and may not be reproduced by, further distributed to or published in whole or in part by, any other person.